Glucose B.Braun

Glucose B.Braun is an intravenous solution containing the active ingredient glucose, anhydrous. It is supplied as a sterile aqueous solution intended for parenteral administration. The product provides a readily available source of carbohydrate for patients requiring intravenous glucose supplementation. Manufactured in the European Union, Glucose B.Braun is classified as a prescription‑only drug and is used in clinical settings for energy support and correction of low blood sugar.

Glucose B.Braun is indicated for clinical situations where rapid provision of carbohydrate energy is required to maintain metabolic stability.

- Management of documented hypoglycemia in hospitalized patients. - Component of total parenteral nutrition regimens for patients unable to receive enteral feeding. - Support during perioperative periods when oral intake is limited. - Treatment of metabolic disorders that impair endogenous glucose production. - Fluid and electrolyte replacement when combined with compatible intravenous solutions. - Adjunctive therapy in critical care settings to maintain blood glucose levels during prolonged fasting.

Glucose B.Braun, when administered intravenously, may be associated with a range of adverse reactions that vary in frequency and clinical significance.

Common: - Local irritation at the infusion site. - Mild hyperglycemia detectable on routine blood glucose monitoring. - Transient nausea or vomiting. - Fluid overload when administered in large volumes. - Mild headache reported during rapid infusion.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Allergic reactions such as urticaria, rash, or anaphylaxis. - Electrolyte disturbances, particularly hyponatremia or hypokalemia. - Metabolic acidosis in patients with impaired lactate clearance. - Hypotension secondary to rapid osmotic shifts.

Glucose B.Braun should be used with attention to patient‑specific factors and clinical conditions to minimize risks and ensure therapeutic effectiveness.

- Verify blood glucose levels before and during infusion to avoid excessive hyperglycemia. - Adjust infusion rate in patients with renal or hepatic impairment. - Use caution in individuals with known hypersensitivity to glucose solutions or excipients. - Monitor fluid balance and electrolytes, especially sodium and potassium, during prolonged therapy. - Avoid concurrent administration with incompatible intravenous drugs that may precipitate precipitation. - Consider special dosing in neonates, infants, and pediatric patients under medical supervision. - Document any adverse reactions promptly in the patient’s medical record.

Glucose B.Braun may interact with other intravenous agents or systemic medications, influencing its safety profile or therapeutic outcome.

Avoid: - Co‑administration with high‑dose insulin infusions without appropriate glucose monitoring. - Simultaneous infusion of calcium‑containing solutions that can cause precipitation. - Use with hyperosmolar agents that may exacerbate fluid overload. - Avoid mixing with acidic solutions that may degrade glucose stability.

Use with caution: - Concurrent use of diuretics, which may alter electrolyte balance during glucose infusion. - Administration alongside catecholamines, as they can affect glucose metabolism. - Overlap with other carbohydrate‑containing parenteral solutions, requiring careful calculation of total glucose load. - Use cautiously in patients receiving beta‑blockers, as they may mask signs of hypoglycemia.